| (Values in U.S. Thousands) | Dec, 2022 | Sep, 2022 | Jun, 2022 | Mar, 2022 | Dec, 2021 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Myrexis Inc (MYRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Myrexis, Inc., formerly known as Myriad Pharmaceuticals, Inc., is a biotechnology company focused on discovering, developing, and commercializing novel therapies for the treatment of cancer. The Company's product pipeline includes Azixa (verubulin, MPC-6827), a microtubule destabilizer for brain cancer; MPC-3100, an HSP90 inhibitor for cancer; MPC-9528, a Cancer Metabolism Inhibitor; MPI-485520, an IKK inhibitor for cancer and inflammation; and others. Myriad Pharmaceuticals, Inc. is based in Salt Lake City, Utah.
Fiscal Year End Date: 06/30